Long-Term Thesis

Figures converted from Swiss francs at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

Long-Term Thesis: What Has To Be True For The Next Decade

The five-to-ten-year question for Sonova is not "is this a good company" — the returns already answer that — but whether a narrow, product-cycle moat can be compounded, undisturbed, across a full decade of demographic tailwind while a strong Swiss franc keeps hiding the result from the reported page. Sonova sits on the single most durable demand setup in medtech (huge untreated hearing loss, under-20% penetration, a 4-6% structural value-growth market) and earns peer-leading, cash-backed returns (73.7% gross margin, ~19% ROCE, ~90% cash conversion) doing it. The catch is that superiority here is re-won every silicon generation, one of three businesses is currently losing share, and the currency the shareholder is paid in has erased local-currency growth for three straight years. The durable thesis is real; it is a lean, not a lay-up.

The underwriting frame in one screen

Source: FY2025/26 Annual Report — 22.5% normalized EBITA margin and 19.0% ROCE [1]; operating free cash flow of $655m [2]; the $7.6 billion revenue ambition by FY2030/31 [3]; ~15% penetration in a developed market like Japan [4].

What has to be true — five load-bearing conditions

A long-term thesis is only as strong as the conditions it silently assumes. Below are the five that carry Sonova's decade. Each is separated into the mechanism, the evidence that it is working today, and the single marker that would prove it working or breaking over the holding period. The rest of the page takes them in turn.

Sources: penetration and demand [5]; Infinio launch [6] and VA share [7]; the growth algorithm [8] and mid-term targets [9]; returns and capital-allocation track record [10]; the FX wedge [11].

Condition 1 — The penetration runway stays open

This is the backbone, and it is the least controversial part of the thesis: hearing loss is a demographic megatrend that the market has barely begun to serve. More than 1.5 billion people live with some degree of hearing loss and over 400 million could benefit from a hearing aid, yet fewer than one in five who would benefit are treated. The industry converges on 4-6% per-annum value growth as the long-run trend — modest unit growth layered with rising average selling prices — with roughly 13 million people fitted and ~23 million aids sold a year [12]. Even in the richest markets penetration is low — only about 15% of those who could benefit in a developed market like Japan use a device [13].

Source: March 2026 Strategy Update — hearing-aid adoption by geography and severity (North America / Western Europe vs. emerging markets) [14].

The durable point for an underwriter is that this growth is structural, not cyclical, over a ten-year window — the gaps above close slowly but reliably as populations age, stigma falls (helped, ironically, by Apple and Sony normalizing ear-worn devices), and emerging-market income rises. The near-term caveat is that hearing aids are a discretionary, big-ticket, often out-of-pocket purchase, so the market does cycle with consumer confidence: it grew below trend through 2025, and Sonova guides to only 2-4% market growth in FY2026/27 before reverting toward the 3-5% mid-term band [15]. A decade thesis can absorb a soft year or two; what it cannot absorb is the market structurally stalling below trend — which is precisely the premise behind the sell-side's skepticism of the $7.6bn ambition (Research tab). The runway is the safest of the five conditions, but it lifts every incumbent equally — it is a reason to like the industry, not evidence that Sonova specifically wins.

Condition 2 — The moat holds through the silicon cycle

This is where the thesis earns or loses its superior-investment claim, because the penetration tailwind is shared by all five manufacturers. Sonova's edge is a genuine but narrow moat (Moat tab): proprietary silicon plus an owned audiology channel, re-won every product cycle rather than structurally entrenched. The current cycle is the proof the moat still cuts: the Phonak Infinio / Sphere platform, built on a proprietary DEEPSONIC AI chip, sold over 1.5 million units in its first 12 months — the most successful launch in company history [16], and the in-the-ear Virto R variant took roughly 60% of the US Veterans Affairs in-the-ear segment, pushing overall VA share to a five-year high [17]. That is measurable, product-driven share capture — the mechanism the ten-year thesis relies on repeating.

The honest limit sits inside the same company. In Cochlear Implants, being late with silicon has cost Sonova share: segment sales fell 11.1% in local currency to $318.0 million on China's volume-based procurement reset and "increased competitive pressure following a product launch by the largest competitor" against an ageing 2021 processor [18]. This is the whole moat thesis compressed into one segment: the regulatory wall keeps entrants out, but it does not protect Sonova from the other two incumbents when its own product is old. Over a decade, the moat is only as durable as Sonova's ability to keep shipping the leading chip — which is why the single most important leading signal in the whole thesis is wholesale local-currency growth holding its pace as the Infinio launch ages, not the launch year itself. Regulation and the 3,600-plus owned clinics widen the moat and slow erosion, but they do not make the silicon edge permanent.

Condition 3 — The growth algorithm compounds to the ambition

Under new CEO Eric Bernard — a direct hire from rival WS Audiology [19] — Sonova has reset around a headline $7.6 billion revenue ambition by FY2030/31 (from ~$4.5bn continuing), underpinned by a mid-term algorithm of 5-10% local-currency sales CAGR and 7-12% Core EBIT CAGR [20] [21]. The algorithm is additive and worth internalizing because it tells you exactly what has to go right: roughly 3-5 points from underlying market growth, 1-3 points from innovation-and-geography share gains, and 1-2 points from bolt-on retail M&A [22].

Source: March 2026 Strategy Update — market growth +3-5%, share gains +1-3%, bolt-on M&A +1-2% (chart uses midpoints) [23].

Two judgments an underwriter has to make about this number. First, the $7.6bn ambition should be treated as a call option, not a base case. It is set by a brand-new team — CEO, CFO, Chair, R&D and operations heads all in seat under 18 months — with no track record together, and the last confident, quantified, top-of-a-reset target (the Sennheiser "fourth core business," pitched at a >EUR 3bn opportunity) ended four years later in a divestment at a $134.3 million after-tax loss (Story tab) [24]. The sell-side is openly skeptical the target is reachable without transformational M&A given a sub-trend end-market (Research tab). Second, and more constructively, the algorithm is achievable on the core alone without heroics: the combined Wholesale-plus-Retail engine grew 7.5% in local currency in FY2025/26, squarely inside the target band, and the retail M&A leg is small, self-funded, and repeatable rather than transformational. Hitting the pace (5-10% LC) is the real thesis; hitting the exact $7.6bn number is a bonus that the franc may deny even if the business delivers.

Source: continuing-operations sales of $4,549m in FY2025/26 [25] and the $7.6bn ambition by FY2030/31 [26]. The bar is an ambition, not a reported figure, and is stated in local-currency terms; a strong franc could hold reported dollars away from it even if the underlying pace is met.

Condition 4 — Returns and the reinvestment runway stay superior

What makes Sonova a candidate superior investment rather than merely a good business is the combination of high returns and a long, capital-light place to redeploy cash. The franchise clears a 73.7% gross margin, spends ~6% of sales on R&D, and converts that into a 22.5% normalized EBITA margin and 19.0% ROCE on a balance sheet at just 1.1x net debt/EBITDA [27]. Management's own 2021-2025 scorecard frames the through-cycle economics: an average Core EBIT margin above 20%, ~90% cash conversion, and 18-20% ROCE [28]. Those returns have persisted above every listed peer for a decade and survived COVID, a chip squeeze, and the loss (and return) of a top US customer — the durability that a snapshot cannot show and the multi-year record can.

Source: normalized EBITA margin and ROCE derived from reported financials, FY2022-FY2026 Annual Reports; FY2025/26 normalized EBITA margin 22.5% and ROCE 19.0% [29]. "Normalized" adds back a recurring stream of "one-time" items, so the true through-cycle margin sits a touch below the line (Forensics tab).

The reinvestment runway is the underrated part of the compounding case. The world's hearing-aid clinics are still mostly independently owned, so the retail land-grab is a decade-long, fragmented consolidation Sonova can fund out of free cash flow: the capital-allocation framework earmarks $101-126 million a year for bolt-on retail acquisitions, ahead of a ~40% dividend payout and inside a 1.0-1.5x leverage ceiling [30]. When a manufacturer owns the clinic, it captures both the device and the fitting margin and locks in a captive channel for its own brands — reinvestment that both grows the base and deepens the moat.

Two disciplines an underwriter should attach to this. First, owned retail is a mediocre business on its own (peer Amplifon earns single-digit EBIT margins), so the reinvestment only compounds if the combined device-plus-fitting economics hold — watch incremental ROCE, not just the pace of store additions. Second, the roll-up has already pushed goodwill to $2,881.6 million, ~87% of equity, a Key Audit Matter [31]. Reported returns therefore carry acquisition-accounting risk if the retail deals sour — the impairment headroom, so far unreserved by the auditor, is the balance-sheet stress to monitor against the China implant weakness.

Condition 5 — Reported dollar earnings re-couple with the engine

This is the condition that decides whether a good decade for the business becomes a good decade for the stock. Sonova reports in Swiss francs but sells in EUR/USD/other, keeping only ~1% of sales and ~15% of its cost base in francs — a structural mismatch it is actively narrowing to widen the natural hedge [32]. The consequence is a persistent wedge: FY2025/26 group sales rose 5.9% in local currency but fell 0.2% in francs as a strong CHF stripped out $279 million of translated revenue [33]. Reported EPS has now fallen three years running — from a $11.61 diluted peak in FY2022/23 [34] to $9.12 including discontinued operations in FY2025/26 [35] — even as the underlying business grew in local currency the entire time.

Source: derived from reported financials, FY2017-FY2026 (converted at historical FX rates); FY2026 EPS of $9.11 is stated including the loss from discontinued operations, with continuing-operations basic EPS of $11.38 [36]; FY2023 diluted peak of $11.61 [37].

The bull reads this as an optical illusion that reverses when the franc stabilizes; the bear reads it as a structural drag management itself guides will continue into FY2027 (Bull/Bear tab). For a decade view the resolution matters less than the recognition: the CHF-denominated report will chronically understate this business, so the USD view is arguably the truer economic picture, and the re-rating catalyst — reported earnings finally inflecting positive — is partly outside management's control. An underwriter should therefore anchor the thesis on local-currency operating metrics (wholesale LC growth, segment margins, ROCE) and treat the reported EPS line as the market's trigger rather than the thesis's truth. The thesis compounds in local currency whether or not the franc ever lets the reported page show it.

What would break the thesis

The failure modes are not symmetric with the bull points — the thesis is most likely to break slowly, through moat erosion at the contested edges, rather than suddenly. Ordered by how early each would warn:

Sources: Cochlear Implants share loss and China VBP [38]; goodwill Key Audit Matter [39]; the OTC category and Sonova's own OTC participation [40]; the Consumer Hearing divestment loss as the capital-allocation precedent [41].

The single most dangerous of these is the first: because share in this oligopoly is re-won every cycle, the same mechanism that handed Sonova +7 points of VA share reverses when a rival ships better silicon — and it is already happening in Cochlear Implants. The structurally slowest but most existential is the low-end flank: Sonova deliberately ceded the fastest-growing OTC tier by divesting Consumer Hearing, a defensible focus decision that nonetheless leaves it with no answer to EssilorLuxottica's ~15,000-store distribution if OTC ever stops expanding the market and starts cannibalizing the prescription funnel it feeds.

The dials and the multi-year watch signals

Sonova is a high-quality, narrow-moat compounder de-rated to ~20x from a 30x-plus history, where the durable engine is intact and the re-rating hinges on variables (the franc, one segment's silicon, a new team's discipline) that a PM can track but not control. The right posture is a lean long that compounds in local currency, underwritten on the Hearing Instruments franchise, with the $7.6bn ambition and the Cochlear Implants turnaround priced as free options. Separate long-term thesis evidence from short-term noise with these signals:

The one-line underwriting verdict: own the compounding engine, price the optionality and the execution honestly, and let the position ride on local-currency operating evidence — not on the franc-clouded reported page or on a new team's ten-year headline.